ArticleDiscover oncology2026
Integrating transcriptomics and Mendelian randomisation identifies immune-related genes causally linked to prostate cancer lymph node metastasis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lymph node metastasis marks a critical transition in prostate cancer progression, yet causal molecular links between primary tumour immunity and metastatic capability remain unclear. We analysed 425 primary prostate cancer patients, integrating transcriptomic profiling with Mendelian randomisation to establish causal relationships between immune cell gene expression and lymph node metastasis. Differential expression analysis identified 131 significantly altered genes between N1 and N0 tumours. Functional enrichment revealed upregulated genes enriched in metal ion homeostasis, whilst downregulated genes involved viral defence and interferon signalling. Mendelian randomisation identified 11 significant causal associations, with 73% demonstrating protective effects. MT1F showed consistent protection across immune cell types, whilst CD38, GNMT, and SLC14A1 paradoxically increased risk despite upregulation in metastatic tumours. A 7-gene prognostic signature independently predicted progression-free survival across validation cohorts. Immune deconvolution analysis revealed high-risk tumours exhibited an immunosuppressive microenvironment with increased regulatory T cells and M2 macrophages, whilst individual signature genes paradoxically showed positive correlations with anti-tumour plasma cells. This study reveals the paradoxical nature of immune-related genes: promoting metastasis when expressed in cancer cells whilst providing protection when expressed in immune cells. Systematic immune suppression creates corrupted microenvironments where protective genes are co-opted for cancer survival. Effective immunotherapy strategies must account for this dual nature, necessitating multi-dimensional precision medicine approaches that target specific cellular compartments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.